Korro Bio reports FY2024 net loss $83.6M; cash $163.1M; KRRO-110 interim readout H2 2025

Korro Bio, Inc.

Net loss $83.6M (vs $81.2M in 2023); R&D expenses $63.6M; G&A $30.5M.
Cash, cash equivalents $163.1M; runway into H2 2026 expected to fund KRRO-110 trial.
KRRO-110 Phase 1/2a REWRITE trial: completed dosing first two cohorts; no SAEs; interim data H2 2025.
FDA granted Orphan Drug Designation for KRRO-110 for AATD.
Collaboration revenue $2.3M from Novo Nordisk partnership; second development candidate expected end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.